Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.37 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637279 | 0.83 | HTR2A (0.42) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL5338566 | 0.78 | SLC6A2 (0.48) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL9052939 | 0.75 | HTR2A (0.39) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL1551814 | 0.74 | DRD2 (0.41) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL1551817 | 0.74 | DRD2 (0.41) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL5624032 | 0.74 | HTR2A (0.41) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL5346300 | 0.73 | SLC6A2 (0.41) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL21815350 | 0.73 | HTR2A (0.41) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL578547 | 0.73 | HTR2A (0.41) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL1552819 | 0.72 | DRD2 (0.40) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289984-A4 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM CO LTD (KR) | 2004-11-24 | — | — | EP | disclosed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
| EP-1289984-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | Dong A Pharmaceutical Co. Ltd. (KR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001094342-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM. CO., LTD. (KR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | ADRB2 4522/4885HTR1A 4403/4885SLC6A2 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.